PTK2 and PTPN11 expression in myelodysplastic syndromes

Authors

  • Mariana Lazarini Hematology and Hemotherapy Center-University of Campinas/Hemocentro-Unicamp; Instituto Nacional de Ciencia e Tecnologia do Sangue
  • Joao Agostinho Machado-Neto Hematology and Hemotherapy Center-University of Campinas/Hemocentro-Unicamp; Instituto Nacional de Ciencia e Tecnologia do Sangue
  • Leticia Frohlich Archangelo Hematology and Hemotherapy Center-University of Campinas/Hemocentro-Unicamp; Instituto Nacional de Ciencia e Tecnologia do Sangue
  • Bruna Fernandes Mendes-Silva Hematology and Hemotherapy Center-University of Campinas/Hemocentro-Unicamp; Instituto Nacional de Ciencia e Tecnologia do Sangue
  • Carolina Louzao Bigarella Mount Sinai School of Medicine; Department of Developmental and Regenerative Biology
  • Fabiola Traina University of Sao Paulo; Ribeirao Preto Medical School; Department of Internal Medicine
  • Sara Teresinha Olalla Saad Hematology and Hemotherapy Center-University of Campinas/Hemocentro-Unicamp; Instituto Nacional de Ciencia e Tecnologia do Sangue

DOI:

https://doi.org/10.1590/clin.v68i10.77016

Abstract

OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src homology 2 domain-containing protein-tyrosine phosphatase 2, in hematopoietic cells from patients with myelodysplastic syndromes. METHODS: Protein tyrosine kinase 2 and tyrosine phosphatase non-receptor type 11 expressions were analyzed by quantitative polymerase chain reaction in bone marrow cells from patients with myelodysplastic syndromes and healthy donors. RESULTS: Protein tyrosine kinase 2 and tyrosine phosphatase non-receptor type 11 expressions did not significantly differ between normal cells and myelodysplastic cells. CONCLUSIONS: Our data suggest that despite the relevance of focal adhesion kinase and src homology 2 domain-containing protein-tyrosine phosphatase 2 in hematopoietic disorders, their mRNA expression do not significantly differ between total bone marrow cells from patients with myelodysplastic syndromes and healthy donors.

Downloads

Download data is not yet available.

Downloads

Published

2013-10-01

Issue

Section

Rapid Communications

How to Cite

PTK2 and PTPN11 expression in myelodysplastic syndromes. (2013). Clinics, 68(10), 1371-1375. https://doi.org/10.1590/clin.v68i10.77016